Blame it on the Democrats or blame it on the Republicans but the stalemate has forced the first US government shutdown in 17 years. Lawmakers failed to agree on a federal budget by the midnight deadline which will start a partial shutdown that will put up to 800,000 federal employees out of work and will shut down some government programs and services. At 3:00 am CT. the ESU is up 8 handles at 1682.25. For the last two weeks the deadlock has helped push the S&P to its largest losing streak of the year: down five days in a row, and down seven out of the last eight sessions. After shaking all the shorts out during the Fed's no-taper the sellers came back in force. The Asian markets closed mostly higher and Europe is following suit, with eight of 12 markets up. Today's economic calendar includes six different economic releases; Motor Vehicle Sales, Gallup US ECI, Redbook, PMI Manufacturing Index, ISM Manufacturing Index and Construction Spending. Welcome to ObamaCare and the government shutdown. As we expected, the S&P futures rallied off the news. With the current shutdown underway this Friday's Labor Department monthly employment report won't be released if the government doesn't reopen in time. While the shutdown is big, the U.S debt ceiling is a much bigger problem. The world's currencies are backed either directly or indirectly by the U.S. dollar and even the possibility of a U.S. refusal to pay its debts can dampen foreign investment and willingness to buy U.S. bonds. We lean to selling the early rally and then buying the weakness. Like the downside, the ESZ is "packed" with upside buy stops. As always, use stops and keep an eye on the 10-handle rule. Don't forget to catch MrTopStep on The Closing Print video. We report directly from the SPX pits, wrapping up the day and positioning for trade tomorrow. OptionsProfits can be followed on Twitter at twitter.com/OptionsProfits MrTopStep can be followed on Twitter at twitter.com/MrTopStep For LIVE futures chat, more information on the 10-handle rule and futures educational content CLICK HERE FOR A SEVEN-DAY FREE TRIAL.
Hot Penny Stocks To Watch For 2015: Targa Resources Inc.(TRGP)
Targa Resources Corp., through its general and limited partner interests in Targa Resources Partners LP, provides midstream natural gas and natural gas liquid (NGL) services in the United States. It engages in gathering, compressing, treating, processing, and selling natural gas, as well as storing, fractionating, treating, transporting, and selling NGLs and NGL products. The company owns interests in or operates approximately 11,372 miles of natural gas pipelines and approximately 800 miles of NGL pipelines, with natural gas gathering systems covering approximately 13,500 square miles and 22 natural gas processing plants with access to natural gas supplies in the Permian Basin, the Fort Worth Basin, the onshore region of the Louisiana Gulf Coast and the Gulf of Mexico. It owns and operates 39 storage wells with a net storage capacity of approximately 65 million barrels; and 16 storage, marine, and transport terminals with above ground storage capacity of approximately 1.4 million barrels. Targa Resources Corp. sells its services to refineries, petrochemical manufacturers, propane distributors, multi-state retailers, independent retailers, and other industrial end-users. The company was founded in 2003 and is based in Houston, Texas.
Advisors' Opinion:- [By Eric Volkman]
The closely related energy firms Targa Resources (NYSE: TRGP ) and Targa Resources Partners (NYSE: NGLS ) are teaming up to return more money to shareholders. Both companies have raised the stockholder payouts for their respective Q1s. For the quarter, Resources will dispense a dividend of $0.4950 per share of its common stock on May 16 to shareholders of record as of April 29. Partners will pay $0.6975 per common unit, to be distributed May 15 to unitholders as of April 29.
Hot Asian Companies To Buy Right Now: Sigma Labs Inc (SGLB)
Sigma Labs, Inc., incorporated on December 23, 1985, has two wholly-owned subsidiaries, B6 Sigma, Inc. and Sumner & Lawrence Limited (dba Sumner Associates). B6 Sigma, Inc. (B6 Sigma) develops precision manufacturing solutions and advanced materials technologies, as well as Reasearch and Development solutions for first-tier integrators and other commercial firms worldwide. Sumner Associates provide consultants to Federal government and commercial clients seeking productive solutions for development technologies. As of December 31, 2012, the Company is engaged in a range of activities, in which it seek to commercialize technologies and products in the industry sectors, which include in process quality assurance for manufacturing; aerospace and defense manufacturing; additive manufacturing; active protection systems for defending light armored vehicles; advanced materials for munitions; advanced materials for sporting goods; advanced manufacturing technologies, and dental implant and biomedical prosthetics technologies.
Sumner & Lawrence Limited (Sumner), based in Santa Fe, New Mexico, provides consulting services to the public sector, especially with regard to emerging technologies and alternative applications of established technologies. Sumner holds ongoing contracts with government agencies and the appropriate levels of security clearance for those contracts. Sumner's clients include the State Department, the Department of Defense, the Department of Energy, various military services and affiliated agencies, the National Laboratories, and contractors to these organizations.
Advisors' Opinion:- [By James E. Brumley]
For veteran traders who've kept tabs on Sigma Labs Inc. (OTCMKTS:SGLB) over the past three months or so, it may be surprising to hear someone suggest it as a buy. Like so many other stocks of its ilk have done since the beginning of the organized market, SGLB went from (proverbially) zero to hero between late May and mid-July with a move from $0.025 to a peak of $0.118 only to fall back to the $0.04 level a couple of weeks later. It's the relatively common "one hit wonder", and if Sigma Labs followed the usual pattern of other small stocks that burned brilliantly for a few days, we wouldn't see anything particularly bullish from SGLB for a few months, if not years.
Hot Asian Companies To Buy Right Now: Cancer Genetics Inc (CGIX)
Cancer Genetics, Inc. (CGI), incorporated on April 8, 1999, is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.
The Company is in the final stages of validating MatBATM-SLL for risk stratification in small lymphocytic lymphoma (SLL), a subset of CLL that presents as a mass, with Memorial Sloan-Kettering Cancer Center and Long Island Jewish / North Shore Hospital. The Company is also internally clinically validating the MatBATM microarray in a variety of additional lymphoma subtypes, including mantle-cell lymphoma (MCL), follicular lymphoma (FL), and diffuses large B cell lymphoma (DLBCL). Its MatBATM array has been designed to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms.
CGI is also developing microarray tests for the diagnosis, prognosis and theranosis of a range of urogenital cancers. These include the UroGenRA microarray for kidney, prostate and bladder cancers and the UGenRA microarray for endometrial (lining of the uterus), ovarian and cervical cancers. UroGenRA detects genomic changes in over 100 r! egions of the human genome with potential diagnostic and/or prognostic value in one or more of these types of cancer. It has initiated clinical validation for UroGenRA targeting kidney and prostate cancers in collaboration with Memorial Sloan-Kettering Cancer Center. Its UGenRA microarray has been designed as a platform to detect genomic changes occurring in 83 regions of the human genome that have been linked to endometrial, ovarian and cervical cancers In addition, it develop and manufacture a portfolio of fluorescence in situ hybridization (FISH) based DNA probes focused on blood-based and solid cancers that it sell outside the United States. The Company laboratory services include: Oncology Testing Services, which are based on its microarray tests and are available only in its clinical laboratory; Esoteric Oncology Testing Services, which it offers a suite of esoteric oncology testing services for hematological, urogenital and HPV-associated cancers, and Clinical Trial Services, which also utilize its clinical laboratory to provide clinical trial services to biopharmaceutical companies and clinical research organizations.
Hematological Cancer Arrays: MatBA-CLL/SLL, Other Mat-BA and LeukA
MatBA is an oligonucleotide-based microarray the Company developed for the analysis of genomic alterations in mature B-cell neoplasms to determine prognosis and theranosis. MatBA incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display clinical, pathologic and genetic complexity. Importantly, the clinical course of the six main subtypes of these neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL).
MatBA is designed to detect genomic copy number chan! ges in ma! ture B-cell neoplasms. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the cancer specimen (array-CGH). Array-CGH utilizes minimal biopsy material and uses DNA as the analyte (the component whose properties are being measured). MatBA was custom-designed to represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA simultaneously permits the detection of genomic gains and losses at multiple locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. For each subtype of B-cell neoplasm, cohorts of specimens with full clinical annotation are evaluated using MatBA to identify associations between single and weighted combinations of genomic gains/losses and clinically relevant endpoints.
The Company offers the application of MatBA for prognostication in one subtype of mature B-cell neoplasm, CLL, where about half of patients experience indolent disease, or slow progression, and the remaining half, a relatively aggressive progression. MatBA-CLL provides genetic-based information to guide clinical management of this disease. In January 2012, MatBA-SLL was approved under CLIA and accordingly may now be offered as an LDT by its laboratory. In January 2013, this assay received approval by CLIA and New-York State for clinical use, and accordingly may now be offered as an LDT by our reference laboratory.
During the year ended December 31, 2012, the Company had similar development of MatBA as a prognostic tool in two of the other main subtypes of mature B-cell lymphomas, namely DLBCL and FL. FL is characterized by a slow progression that in up to approximately 60% of cases transforms to DLBCL, an aggressive lymphoma. Prognostic and theranostic biomarkers of therapeutic options are req! uired for! these diseases.
Urogenital cancer arrays: UroGenRA, UGenRA
The UroGenRA microarray provides diagnostic and prognostic analysis for kidney, bladder and prostate cancer. Its initial launch, UroGenRA-Kidney targets kidney cancer. It also develops extensions of UroGenRA for bladder and prostate cancers. UGenRA provide diagnostic, prognostic and theranostic information for the primary gynecological cancers, cervical, ovarian and endometrial. UroGenRA is a CGH-based array which serves as a platform for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It represents 101 regions of the human genome potentially with diagnostic, prognostic and/or theranostic value in one or more of these types of cancers. UroGenRA-Kidney For kidney cancer, UroGenRA is specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, chromophobe and oncocytoma), which is critical to patient management and treatment protocols.
UroGenRA-Prostate for prostate cancer, UroGenRA use prostate core/needle biopsy to assess genomic variability of the cancer and help in the identification of biomarkers for assessment of the risk of recurrence, to assess treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. UroGenRA-Prostate is in the commercial development stage. UroGenRA-Bladder is a diagnosed bladder cancers are defined by the fact or extent of invasion of the muscle. UroGenRA-Bladder is in the clinical development stage.
UGenRA for Endometrial, Ovarian and Cervical Cancers
UGenRA is designed as a platform to detect gains and losses of genomic material in 83 regions of the chromosome associated with responses to particular therapies in patients with endometrial, ovarian and cervical. UGenRA-Endometrial Endometrial cancer is common cancer in women in the United States. In this disease, endometrial hyperplasia is a precursor lesion of endometr! ioid endo! metrial carcinoma (EEC). UGenRA Endometrial is in the clinical development stage.
UGenRA-Ovarian is cases of ovarian cancer. UGenRA Ovarian is in the clinical development stage. As of December 31, 2012, UGenRA-Cervical was approximately 11,270 cases of cervical cancer diagnosed and approximately 4,290 deaths from cervical cancer in the United States. UGenRA Cervical is in the clinical development stage.
Advisors' Opinion:- [By John Udovich]
Cancer has been one of the hotter segments of the sizzling biotech sector this year with small cap cancer stocks�Genetics Inc (NASDAQ: CGIX), GTx, Inc (NASDAQ: GTXI) and MetaStat Inc (OTCMKTS: MTST) being among those involved in cancer research or treatment producing noteworthy news for investors to digest. Just consider the following:
- [By Lauren Pollock]
Biopharmaceutical development company CytRx Corp.(CYTR) and early-stage diagnostics company Cancer Genetics Inc.(CGIX) separately disclosed plans to sell stock. CytRx, whose offering of 10 million shares priced at an 18% discount, is aiming to raise money to fund its clinical trials, while Cancer Genetics wants to hire more sales and marketing personnel, as well as fund research and development. CytRx dropped, while Cancer Genetics fell.
Hot Asian Companies To Buy Right Now: Moog Inc (MOGA)
Moog Inc. (Moog), incorporated on August 1, 1951, is a designer, manufacturer and integrator of precision motion and fluid controls and systems for a range of applications in aerospace and defense and industrial markets. The Company operates in five segments: Aircraft Controls, Space and Defense Controls, Industrial Systems, Components and Medical Devices. Within the aerospace and defense market, its products and systems include military and commercial aircraft flight controls, thrust vector controls for space launch vehicles, controls for gun aiming, stabilization and automatic ammunition loading for armored combat vehicles, satellite positioning controls and controls for steering tactical and strategic missiles. In July 2012, it acquired American Pacific Corporation's In-Space Propulsion business. In August 2012, the Company acquired Tritech International Limited. In January 2013, the Company acquired Broad Reach Engineering Company. Effective March 21, 2013, the Company acquired Aspen Motion Technologies Inc. In July 2013, Moog Inc completed the sale of its Buffalo, New York operations of Ethox Medical to Dempsey Ventures.
Aircraft Controls
The Company designs, manufactures and integrates primary and secondary flight controls for military and commercial aircraft and provide aftermarket support. The Company systems are used in commercial transports, supersonic fighters, multi-role military aircraft, business jets and rotorcraft. The Company also supply ground-based navigation aids. During the fiscal year ended September 29, 2012 (fiscal 2012). The Company is working on several development programs, including the F-35 Joint Strike Fighter, Boeing 787 Dreamliner, COMAC C919, Airbus A350XWB, several business jet programs and a new military air refueling tanker KC-46. The F-35 flight test phase has expanded covering three variants and initial production is increasing with aircraft being delivered to international partners. The Company�� military production programs include th! e F/A-18E/F Super Hornet, the V-22 Osprey tiltrotor, the Black Hawk/Seahawk helicopter and the F-35. The Company�� commercial production programs include the full line of Boeing 7-series aircraft, Airbus A330 and a range of business jets.
The Company competes with Parker Hannifin, UTC (Goodrich, Hamilton Sundstrand), Liebherr, Nabtesco, Woodward Governor and Curtiss-Wright.
Space and Defense Controls
Space and Defense Controls provides controls for satellites and space vehicles, launch vehicles, armored combat vehicles, tactical and strategic missiles, security and surveillance and other defense applications. For commercial and military satellites, The Company design, manufacture and integrate propulsion systems and components (attitude control and orbit insertion) and actuation systems and components for deploying solar panels and antennae pointing. The Atlas, Delta and Ariane launch vehicle programs use its steering and propulsion controls. The Company is also developing products for NASA�� new Space Launch System.
The Company designs and builds steering and propulsion controls for tactical and strategic missile programs, including Hellfire, TOW and Trident. The Company supply valves and steering controls on the U.S. National Missile Defense Agency's Ballistic Missile Defense initiative. The Company designs and manufactures systems for gun aiming, stabilization, turrets, automatic ammunition loading and driver vision enhancement on armored combat vehicles for a range of international and United States customers. The Company designs, builds and integrate stores management systems for light attack aerial reconnaissance platforms. The Company also designs and builds high power, quiet controls for naval surface ship and submarine applications.
The Company competes with Honeywell, Parker Hannifin, Vacco, Valvetech, Marotta, SABCA, ESW, Aerojet, Snecma, Valcor, Aeroflex, UTC (Hamilton Sundstrand), Limitorque, Sargeant Industries, RVision! , Directe! d Perception, ATA Engineering, CDA InterCorp, RUAG, Rockwell Collins, Woodward Governor, Sierra-Nevada, Vicon, Videotec and Lord Corp.
Industrial Systems
Industrial Systems serves a global customer base across a range of markets. For wind energy, Industrial Systems serves a global customer base across a variety of markets. For wind energy, The Company designs and manufactures electric pitch controls and blade monitoring systems for wind turbines. The Company supply electromechanical motion simulation bases for the flight simulation and training markets. For the plastics making machinery market, the Company designs, manufactures and integrates systems for all axes of injection and blow molding machines. For the test markets, the Company supply controls for automotive, structural and fatigue testing.
The Company supply electromechanical motion simulation bases for the flight simulation and training markets. In the power generation market, the Company designs, manufactures and integrates complete control assemblies for fuel, steam and variable geometry control applications. For the test markets, the Company supply controls for automotive, structural and fatigue testing. Metal forming markets use its systems to provide precise control of position, velocity, force, pressure, acceleration and other critical parameters. Heavy industry uses its high precision electrical and hydraulic servovalves for steel and aluminum mill equipment. Other markets include oil exploration, material handling, auto racing, carpet tufting, paper and lumber mills.
The Company competes with Bosch Rexroth, Danaher, Baumueller, Siemens, SSB, Parker Hannifin, Suzhou ReEnergy, MTS Systems Corp., Exlar and Hydraudyne.
Components
The Components segment�� product categories are slip rings, fiber optic rotary joints and motors. Slip rings and fiber optic rotary joints use sliding contacts and optical technology to allow unimpeded rotation while delivering power ! and data ! through a rotating interface. They come in a range of sizes that allow them to be used in many applications, including diagnostic imaging computed tomography (CT) scan medical equipment featuring high-speed data communications, de-icing and data transfer for rotorcraft, forward-looking infrared camera installations, radar pedestals, satellites, missiles, wind turbines, surveillance cameras and remotely operated vehicles and floating platforms for offshore oil exploration.
The Company�� motors are used in an equally range of markets, many of which are the same as for slip rings. Components designs and manufactures a series of fractional horsepower brushless motors that provide extremely low acoustic noise and reliable long life operation, with the market being sleep apnea equipment. Industrial markets use its motors for material handling and electric pumps. Military applications use its motors for gimbals, missiles and radar pedestals. Components��other product lines include electromechanical actuators for military, aerospace and commercial applications, fiber optic modems that provide electrical-to-optical conversion of communication and data signals, avionic instrumentation, optical switches and resolvers.
The Company competes with Danaher, Allied Motion, Ametek, Woodward MPC, Axsys, Schleifring, Airflyte, Smiths, Kearfott and Stemmann.
Medical Devices
Medical Devices segment operates within four medical devices market areas: infusion therapy, enteral clinical nutrition, sensors and surgical hand pieces. For infusion therapy, its primary products are electronic ambulatory infusion pumps along with the associated administration sets. Applications of these products include hydration, nutrition, patient-controlled analgesia, local anesthesia, chemotherapy and antibiotics. The Company manufactures and distributes a complete line of portable pumps, stationary pumps and disposable sets that are used in the delivery of enteral nutrition for patients in ! their own! homes, hospitals and long-term care facilities. The Company manufactures and distributes ultrasonic and optical sensors used to detect air bubbles in infusion pump lines and ensure accurate fluid delivery. The Company�� surgical hand pieces are used to safely fragment and aspirate tissue in common medical procedures such as cataract removal.
The Company competes with B. Braun, CareFusion, Smiths Medical, Hospira, Alcon, Baxter International, CME, I-Flow, Covidien, Etalon, Introtek and Ross (Abbott).
Advisors' Opinion:- [By Seth Jayson]
Moog (NYSE: MOGA ) reported earnings on April 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 30 (Q2), Moog met expectations on revenues and beat expectations on earnings per share.
Hot Asian Companies To Buy Right Now: PDF Solutions Inc.(PDFS)
PDF Solutions, Inc. provides infrastructure technologies and services for the design and manufacture of integrated circuits (IC) in Asia, the United States, and Europe. It offers manufacturing process solutions that include process research and development, and process integration and yield ramp; volume manufacturing solutions; and design-for-manufacturability (DFM) solutions, such as logic DFM, circuit level DFM, memory DFM, and pdBRIX Physical IP solutions. The company also offers characterization vehicle (CV) infrastructure, which includes CV test chips, pdCV analysis software, and pdFasTest electrical wafer test system; Yield Ramp Simulator software that analyzes an IC design to compute its systematic and random yield loss; and Circuit Surfer software, which estimates the parametric performance yield and manufacturability of analog/mixed-signal/RF blocks. In addition, it provides pdBRIX platform, which includes software for identifying and developing a set of physical IP building blocks that are tailored to a given manufacturing process and target product application; dataPOWER YMS platform that collects yield data, loads, and stores it in an integrated database and allows product engineers to identify and analyze production yield issues; FDC software, which provides fault detection and classification capabilities to identify sources of process variations and manufacturing excursions by monitoring equipment parameters; and YA-FDC service and software platform that allows online modeling to create real-time virtual measurements of final product attributes during processing. PDF Solutions sells its technologies and services through direct sales force, sales representatives, and strategic alliances to integrated device manufacturers, fabless semiconductor design companies, and foundries in the microprocessors, memory, graphics, image sensor solutions, and communications segments. The company was founded in 1992 and is headquartered in San Jo se, California.
Advisors' Opinion:- [By Roberto Pedone]
PDF Solutions (PDFS) provides infrastructure technologies and services to improve yield and optimize performance of integrated circuits. This stock closed up 2.6% at $21.51 in Friday's trading session.
Friday's Volume: 543,000
Three-Month Average Volume: 112,159
Volume % Change: 393%From a technical perspective, PDFS trended up here right above some near-term support at $20.50 and into new 52-week-high territory with above-average volume. This stock has been uptrending strong for the last three months, with shares moving higher from its low of $14.95 to its intraday high on Friday of $21.64. During that move, shares of PDFS have been consistently making mostly higher lows and higher highs, which is bullish technical price action. That move has also been accompanies by heavy upside volume flows since mid-July.
Traders should now look for long-biased trades in PDFS as long as it's trending above some near-term support at $20.50 or above its 50-day at $19.06 and then once it sustains a move or close above Friday's high of $21.64 with volume that's near or above 112,159 shares. If we get that move soon, then PDFS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $25 to $28.
Hot Asian Companies To Buy Right Now: Fortis Inc (FRTSF.PK)
Fortis Inc. (Fortis) is an investor-owned gas and electric distribution utility in Canada. Its regulated utilities account for 90 % of total assets and serve customers across Canada and in New York State and the Caribbean. Fortis owns non-regulated hydroelectric generation assets in Canada, Belize and Upstate New York. The Company's non-utility investments are comprised of hotels and commercial real estate in Canada and petroleum supply operations in the Mid-Atlantic Region of the United States. Advisors' Opinion:- [By Markus Aarnio]
Emera's competitors include Northland Power (NPIFF.PK), Fortis (FRTSF.PK), and Atlantic Power (AT). Northland Power has seen insider buying in August and has a dividend yield of 7.6%. Fortis has seen both insider buying and insider selling in August. Fortis has a dividend yield of 4.1%. Atlantic Power saw insider buying last time in April. Atlantic Power has a dividend yield of 9.4%.
No comments:
Post a Comment